Company Directory

Surface acoustic wave nebuliser platform for inhaled drug delivery

Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations, and other hard-to-nebulise drugs that currently lack viable pulmonary delivery routes. The company works with pharmaceutical partners to validate the technology ahead of regulatory submission.

Xeno nucleic acid binders for targeted drug delivery

Xterna is a biotechnology company developing cell-specific molecular binders composed of xeno nucleic acids (XNAs), chemically modified nucleic acids distinct from naturally occurring DNA and RNA. XNA-based binders are engineered to target cell types that evade conventional antibody-based approaches, enabling drug delivery to previously inaccessible tissues. The platform is designed to carry nucleic acid therapeutic payloads, improving delivery precision and reducing off-target effects.

Programmable gene control platform for advanced cell therapies

Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved safety profiles. Laverock's internal pipeline targets oncology and genetic medicine, with lead programmes in T-cell and macrophage immunotherapy.

Tissue-targeted gene and RNA delivery platforms for rare and neurological disease

Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues, while a complementary system targets cartilage and joint structures. The lead programme is an investigational lentiviral vector delivering a functional gene for Hurler syndrome, a lysosomal storage disorder.

Cell-specific mRNA delivery platform for genetic medicines

Nuntius Therapeutics is a London-based biotechnology company developing mRNA therapies using proprietary peptide dendrimer and lipid-based nanocarriers designed to deliver genetic payloads to tissues and cell types beyond the liver. The platform combines machine learning-guided carrier design with engineered mRNA payloads to improve delivery specificity and protein expression. Pipeline focus areas include oncology, respiratory disease and neurodegeneration. In 2024 the company announced a collaboration with Taiho Pharmaceutical for mRNA cancer immunotherapy applications.

Modular automated RNA manufacturing platform

Centillion is a UK biotech company whose platform integrates synthesis, purification, and formulation stages using continuous flow chemistry to produce mRNA and self-amplifying RNA at research and production scale. The platform supports process development through to regulatory-ready CMC packages and is available as a service, under licence, or through joint development programmes. First GMP installation was completed at Quotient Sciences in Alnwick in 2024.

Next-generation lipid nanoparticle platform for RNA vaccines and medicines

NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of administration, and improved safety profiles. Applications span infectious disease vaccines, oncology, and broader RNA medicine programmes. NeoVac has advanced a Phase I mRNA vaccine candidate in UK volunteers.

RNA therapeutics targeting cellular senescence and age-related disease

Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases. Lead indications include idiopathic pulmonary fibrosis, osteoarthritis, and age-related macular degeneration. The company also pursues a cosmeceutical programme targeting aesthetic signs of skin ageing.

Genomics platform developing RNA therapies for chronic liver disease

Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug targets. RNA therapy candidates are developed in-house, with a focus on fibrosis and cirrhosis. Ochre operates labs in Oxford, New York, and Taipei, and has research partnerships with GSK and Boehringer Ingelheim.

National innovation centre accelerating drug discovery

Medicines Discovery Catapult (MDC) is an independent, not-for-profit national innovation centre that supports UK medicines discovery organisations across the full drug discovery pipeline. MDC provides access to specialist laboratory technologies, computational and AI-driven tools, translational R&D expertise, and collaborative research partnerships. It works with SMEs, biotechs, academics, and charities to de-risk drug discovery projects, validate novel technologies, and strengthen the commercial and scientific case for clinical progression.

MicroRNA therapeutics for tendon and musculoskeletal disease

Causeway Therapeutics is a clinical-stage biotechnology company developing first-in-class microRNA therapies for musculoskeletal and age-related conditions. Its lead asset TenoMiR (CWT-001) is a synthetic miR-29a mimic delivered by single intratendinous injection that promotes collagen remodelling and tendon repair. Lead indications are lateral epicondylitis and rotator cuff tendinopathy, with Phase 2 data reported in 2025 and Phase 3 planned. The pipeline includes additional programmes targeting cardiovascular disease and intervertebral disc disease.

Contract synthesis of custom and modified oligonucleotides

ATDBio is a UK-based contract oligonucleotide synthesis company specialising in chemically modified DNA and RNA oligonucleotides for therapeutic and diagnostic applications. Its services span discovery through preclinical scale, encompassing antisense oligonucleotides, siRNA, aptamers, and diagnostic probes, with a broad range of backbone, sugar, and terminal modifications including LNA, phosphorothioate, and GalNAc conjugates. Laboratories are ISO 9001 certified and based at the University of Southampton and Oxford Science Park.